GENE ONLINE|News &
Opinion
Blog

2026-04-23|

AdvisorShares Issues Statement on Federal Decision to Finalize Cannabis Rescheduling

by GOAI
Share To

AdvisorShares, an asset management firm specializing in exchange-traded funds (ETFs), released a statement following the federal government’s decision to finalize the rescheduling of cannabis. The announcement comes as regulatory changes surrounding cannabis continue to evolve at the national level, potentially impacting industries and markets tied to the substance.

The statement from AdvisorShares addressed the implications of this policy shift, particularly for businesses and investors involved in cannabis-related sectors. The firm highlighted that the rescheduling could lead to significant changes in how cannabis is regulated, distributed, and taxed across the United States. AdvisorShares also noted potential effects on financial markets, including shifts in investor sentiment and adjustments within portfolios that include cannabis-focused investments such as their ETF product MSOS. While specifics regarding these impacts remain uncertain, the company emphasized its commitment to monitoring developments closely and keeping stakeholders informed.

Further details about AdvisorShares’ perspective on this issue can be found through their official communication channels.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 23, 2026

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
LATEST
Ellomay Capital Completes Sale of Dorad Energy Holdings on May 10, 2026
2026-05-10
Digitalis Glycosides Studied for Heart Failure Treatment at ESC Heart Failure 2026 Congress
2026-05-10
Digoxin Lowers Death Risk and Heart Failure in Rheumatic Heart Disease Patients, Study Finds
2026-05-10
New Test Detects Biomarkers for Frontotemporal Lobar Degeneration, a Rare Dementia Affecting Over 57 Million Globally
2026-05-10
India’s Pharmaceutical Growth Slows: Industry Needs New Strategies
2026-05-10
MoonLake Immunotherapeutics Concludes Pre-BLA Meeting with FDA and Reports Q1 2026 Financial Results
2026-05-10
New Method Allows Repeated Genetic Data Extraction From Living Cells Without Destruction
2026-05-10
Scroll to Top